Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets March 31, 2026 Revenues of €1.8 billion (-4% versus PY) driven by solid performance across key therapeutic areas and global markets, partially offset by Ocaliva® withdrawal impact. Adjusted EBITDA2 of €350 million (-18% versus PY) underpinned by streamlined operational efficiencies and operating model evolution. Like-for-like Revenues up 7%, and EBITDA up 20%, adjusted for voluntarily withdrawal of Ocaliva® from US market. Marketing application under EMA review for the use of Jyseleca® in a new indication of axial spondyloarthritis (axSpA), a chronic inflammatory arthritis, to address unmet patient needs, submitted following the reporting period. Following the reporting period, agreement with GSK plc for worldwide exclusive rights to develop, manufacture and commercialise linerixibat; subsequently granted FDA approval for the US market (March 2026).
AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial March 31, 2026 Early biomarker and safety data show encouraging signals with plans to present additional data in 2H 2026 AviadoBio secures strategic investment from The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) through their Treat FTD Fund to support ASPIRE-FTD Trial AviadoBio regains full rights to AVB-101 gene therapy program
FuneralExperts.com Joins Forces with NotifyNOW and InheritNOW to Transform Support for Bereaved Families Across the UK March 31, 2026 FuneralExperts.com, the UK’s leading independent and impartial frontline bereavement support service, has announced a new partnership with The Estate Registry’s services NotifyNOW and InheritNOW to transform the way families are supported following a death – helping them notify organisations efficiently and access vital financial assistance before probate is granted. Through the partnership, families supported by [...]
Provation Introduces Real-Time, AI-Powered Documentation Assist for GI Procedures March 30, 2026 Provation, a leading provider of clinical productivity software, announces the launch of Provation® Mira Documentation Assist, a voice-driven documentation capability within its cloud-based GI procedure platform, Provation® Apex, enabling real-time structured documentation during procedures. This hands-free technology allows clinicians to document in real-time by simply speaking, reducing the need for manual data entry and post-procedure [...]
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote March 30, 2026 Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased. Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks. Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority.
AngloGold Ashanti Holdings plc Announces Capped Cash Tender Offers for Part of Its 3.375% Notes Due 2028, 3.750% Notes Due 2030 and 6.500% Notes Due 2040 March 30, 2026 AngloGold Ashanti Holdings plc (the “Offeror”), a company incorporated under the laws of the Isle of Man, announces today the offers to purchase for cash the outstanding series of its (i) 3.375% notes due 2028 (the “2028 Notes”), (ii) 3.750% notes due 2030 (the “2030 Notes”) and (iii) 6.500% notes due 2040 (the “2040 Notes” [...]
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy March 30, 2026 Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen.
AltynGold Plc (“AltynGold” or the “Company”) Participation in MINEX Kazakhstan 2026 March 30, 2026 AltynGold (LSE:ALTN), the Kazakh metals, mining and energy group, is pleased to announce its participation as an exhibitor at the MINEX Kazakhstan Mining & Exploration Forum 2026, taking place 14–16 April 2026 in Astana, Kazakhstan. MINEX Kazakhstan is one of the region’s leading mining and exploration forums, bringing together government representatives, mining companies, investors and [...]
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations March 30, 2026 Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, [...]
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth March 27, 2026 Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD [...]
